

Karen Brown

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4893379/publications.pdf>

Version: 2024-02-01

99
papers

9,966
citations

101543

36
h-index

37204

96
g-index

100
all docs

100
docs citations

100
times ranked

19983
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
2	Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis. <i>Cancer Research</i> , 2010, 70, 9003-9011.	0.9	542
3	Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer Patients. <i>Cancer Research</i> , 2010, 70, 7392-7399.	0.9	511
4	Clinical trials of resveratrol. <i>Annals of the New York Academy of Sciences</i> , 2011, 1215, 161-169.	3.8	400
5	What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol. <i>PLoS ONE</i> , 2011, 6, e19881.	2.5	375
6	Sulfate Metabolites Provide an Intracellular Pool for Resveratrol Generation and Induce Autophagy with Senescence. <i>Science Translational Medicine</i> , 2013, 5, 205ra133.	12.4	163
7	Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. <i>Cancer Letters</i> , 2015, 364, 135-141.	7.2	147
8	Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. <i>Science Translational Medicine</i> , 2015, 7, 298ra117.	12.4	137
9	Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. <i>Journal of Nutrition</i> , 2019, 149, 1133-1139.	2.9	125
10	Pilot Study of Oral Anthocyanins for Colorectal Cancer Chemoprevention. <i>Cancer Prevention Research</i> , 2009, 2, 625-633.	1.5	109
11	Resveratrol in human cancer chemoprevention – Choosing the “right” dose. <i>Molecular Nutrition and Food Research</i> , 2012, 56, 7-13.	3.3	102
12	Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: Impact on measures of decision making and satisfaction.. <i>Health Psychology</i> , 2009, 28, 11-19.	1.6	94
13	Direct molecular targets of resveratrol: identifying key interactions to unlock complex mechanisms. <i>Annals of the New York Academy of Sciences</i> , 2015, 1348, 124-133.	3.8	91
14	Pharmacokinetics and metabolism of the putative cancer chemopreventive agent cyanidin-3-glucoside in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1261-1268.	2.3	89
15	Prolonged Biologically Active Colonic Tissue Levels of Curcumin Achieved After Oral Administration – A Clinical Pilot Study Including Assessment of Patient Acceptability. <i>Cancer Prevention Research</i> , 2013, 6, 119-128.	1.5	89
16	Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. <i>Carcinogenesis</i> , 2002, 23, 1897-1902.	2.8	81
17	Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. <i>Seminars in Oncology</i> , 2002, 29, 36-40.	2.2	80
18	Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2011, 129, 476-486.	5.1	77

#	ARTICLE	IF	CITATIONS
19	Curcumin: The potential for efficacy in gastrointestinal diseases. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 519-534.	2.4	73
20	Chemoprevention of Breast Cancer by Tamoxifen: Risks and Opportunities. <i>Critical Reviews in Toxicology</i> , 2000, 30, 571-594.	3.9	72
21	Cancer Prevention Europe. <i>Molecular Oncology</i> , 2019, 13, 528-534.	4.6	70
22	Development of Dietary Phytochemical Chemopreventive Agents: Biomarkers and Choice of Dose for Early Clinical Trials. <i>Cancer Prevention Research</i> , 2009, 2, 525-530.	1.5	66
23	Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen. <i>Expert Opinion on Drug Safety</i> , 2002, 1, 253-267.	2.4	62
24	Applications of accelerator mass spectrometry for pharmacological and toxicological research. <i>Mass Spectrometry Reviews</i> , 2006, 25, 127-145.	5.4	62
25	InÂvivo relevant mixed urolithins and ellagic acid inhibit phenotypic and molecular colon cancer stem cell features: A new potentiality for ellagitannin metabolites against cancer. <i>Food and Chemical Toxicology</i> , 2016, 92, 8-16.	3.6	58
26	Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. <i>Trials</i> , 2015, 16, 110.	1.6	57
27	Accelerator Mass Spectrometry for Biomedical Research. <i>Methods in Enzymology</i> , 2005, 402, 423-443.	1.0	56
28	Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes. <i>Scientific Reports</i> , 2018, 8, 12096.	3.3	55
29	Resveratrol in the management of human cancer: how strong is the clinical evidence?. <i>Annals of the New York Academy of Sciences</i> , 2013, 1290, 12-20.	3.8	54
30	Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. <i>Cancer Research</i> , 2003, 63, 8461-5.	0.9	53
31	Flavones as Colorectal Cancer Chemopreventive Agentsâ€”Phenol- <i>O</i> -Methylation Enhances Efficacy. <i>Cancer Prevention Research</i> , 2009, 2, 743-750.	1.5	52
32	Longitudinal Changes in Patient Distress following Interactive Decision Aid Use among <i>BRCA1/2</i> Carriers. <i>Medical Decision Making</i> , 2011, 31, 412-421.	2.4	51
33	Resveratrol-sulfates provide an intracellular reservoir for generation of parent resveratrol, which induces autophagy in cancer cells. <i>Autophagy</i> , 2014, 10, 524-525.	9.1	42
34	Cognitive and emotional factors predicting decisional conflict among high-risk breast cancer survivors who receive uninformative <i>BRCA1/2</i> results.. <i>Health Psychology</i> , 2009, 28, 569-578.	1.6	41
35	N-Methylpurine DNA Glycosylase Plays a Pivotal Role in the Threshold Response of Ethyl Methanesulfonateâ€”Induced Chromosome Damage. <i>Toxicological Sciences</i> , 2011, 119, 346-358.	3.1	39
36	Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen. <i>Carcinogenesis</i> , 1999, 20, 2011-2016.	2.8	38

#	ARTICLE	IF	CITATIONS
37	Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: Relationship with silibinin levels. <i>European Journal of Cancer</i> , 2008, 44, 898-906.	2.8	38
38	Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents. <i>European Journal of Medicinal Chemistry</i> , 2012, 54, 952-958.	5.5	38
39	Determination of Endogenous and Exogenously Derived N7-(2-Hydroxyethyl)guanine Adducts in Ethylene Oxide-Treated Rats. <i>Chemical Research in Toxicology</i> , 2007, 20, 290-299.	3.3	35
40	Dose-Response Relationships for N7-(2-Hydroxyethyl)Guanine Induced by Low-Dose [¹⁴ C]Ethylene Oxide: Evidence for a Novel Mechanism of Endogenous Adduct Formation. <i>Cancer Research</i> , 2009, 69, 3052-3059.	0.9	34
41	Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity. <i>Cell Death and Disease</i> , 2018, 9, 894.	6.3	34
42	Is tamoxifen a genotoxic carcinogen in women?. <i>Mutagenesis</i> , 2009, 24, 391-404.	2.6	33
43	The role of cancer stem cells in the anti-carcinogenicity of curcumin. <i>Molecular Nutrition and Food Research</i> , 2013, 57, 1630-1637.	3.3	33
44	Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs' attitudes. <i>British Journal of General Practice</i> , 2017, 67, e414-e427.	1.4	33
45	Time for a European initiative for research to prevent cancer: A manifesto for Cancer Prevention Europe (CPE). <i>Journal of Cancer Policy</i> , 2018, 17, 15-23.	1.4	32
46	The role of stromal fibroblasts in lung carcinogenesis: A target for chemoprevention?. <i>International Journal of Cancer</i> , 2016, 138, 30-44.	5.1	31
47	Development of an Interactive Decision Aid for Female BRCA1/BRCA2 Carriers. <i>Journal of Genetic Counseling</i> , 2003, 12, 109-129.	1.6	29
48	Tamoxifen Forms DNA Adducts in Human Colon after Administration of a Single [¹⁴ C]-Labeled Therapeutic Dose. <i>Cancer Research</i> , 2007, 67, 6995-7002.	0.9	29
49	Techniques: The application of accelerator mass spectrometry to pharmacology and toxicology. <i>Trends in Pharmacological Sciences</i> , 2004, 25, 442-447.	8.7	27
50	Therapeutic cancer prevention: achievements and ongoing challenges – a focus on breast and colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 579-590.	4.6	27
51	Mutagenicity of DNA adducts derived from ethylene oxide exposure in the pSP189 shuttle vector replicated in human Ad293 cells. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2009, 678, 129-137.	1.7	26
52	DNA Adducts Formed from 4-Hydroxytamoxifen Are More Mutagenic than Those Formed by \pm -Acetoxymtamoxifen in a Shuttle Vector Target Gene Replicated in Human Ad293 Cells. <i>Biochemistry</i> , 2002, 41, 8899-8906.	2.5	25
53	Simultaneous detection of five different 2-hydroxyethyl-DNA adducts formed by ethylene oxide exposure, using a high-performance liquid chromatography/electrospray ionisation tandem mass spectrometry assay. <i>Rapid Communications in Mass Spectrometry</i> , 2008, 22, 19-28.	1.5	25
54	BRCA1/2 test results impact risk management attitudes, intentions, and uptake. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 755-764.	2.5	25

#	ARTICLE	IF	CITATIONS
55	Anthocyanin-rich red grape extract impedes adenoma development in the ApcMin mouse: Pharmacodynamic changes and anthocyanin levels in the murine biophase. <i>European Journal of Cancer</i> , 2010, 46, 811-817.	2.8	25
56	Determination of anthocyanins in the urine of patients with colorectal liver metastases after administration of bilberry extract. <i>Biomedical Chromatography</i> , 2011, 25, 660-663.	1.7	25
57	Determination of DNA Damage in F344 Rats Induced by Geometric Isomers of Tamoxifen and Analogues. <i>Chemical Research in Toxicology</i> , 1998, 11, 527-534.	3.3	22
58	Preclinical Colorectal Cancer Chemopreventive Efficacy and p53-Modulating Activity of 3,4,5-Trimethoxyflavonol, a Quercetin Analogue. <i>Cancer Prevention Research</i> , 2010, 3, 929-939.	1.5	22
59	Translating Curcumin to the Clinic for Lung Cancer Prevention: Evaluation of the Preclinical Evidence for Its Utility in Primary, Secondary, and Tertiary Prevention Strategies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 350, 483-494.	2.5	22
60	Detection of Plasma Curcuminoids from Dietary Intake of Turmeric-Containing Food in Human Volunteers. <i>Molecular Nutrition and Food Research</i> , 2018, 62, e1800267.	3.3	21
61	Targeting cancer stem-like cells using dietary-derived agents "Where are we now?". <i>Molecular Nutrition and Food Research</i> , 2016, 60, 1295-1309.	3.3	19
62	Synthesis and spectroscopic characterization of site-specific 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine oligodeoxyribonucleotide adducts. <i>Nucleic Acids Research</i> , 2001, 29, 1951-1959.	14.5	18
63	Pharmacokinetics in mice and metabolism in murine and human liver fractions of the putative cancer chemopreventive agents 3,4,5,7-pentamethoxyflavone and tricetin (4,5,7-trihydroxy-3,5-dimethoxyflavone). <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 255-263.	2.3	17
64	Methods for the Detection of DNA Adducts. <i>Methods in Molecular Biology</i> , 2012, 817, 207-230.	0.9	17
65	Structural characterization of carcinogen-modified oligodeoxynucleotide adducts using matrix-assisted laser desorption/ionization mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2003, 38, 68-79.	1.6	16
66	A Presurgical Study of Curcumin Combined with Anthocyanin Supplements in Patients with Colorectal Adenomatous Polyps. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11024.	4.1	16
67	Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods. <i>Mutagenesis</i> , 2005, 20, 115-124.	2.6	15
68	Mutation Spectra Induced by $\hat{\pm}$ -Acetoxytamoxifen~DNA Adducts in Human DNA Repair Proficient and Deficient (Xeroderma Pigmentosum Complementation Group A) Cells. <i>Biochemistry</i> , 2005, 44, 8198-8205.	2.5	15
69	A novel ¹⁴ C-postlabeling assay using accelerator mass spectrometry for the detection of O6-methyldeoxy-guanosine adducts. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 883-891.	1.5	15
70	A Systematic Review Assessing Clinical Utility of Curcumin with a Focus on Cancer Prevention. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000977.	3.3	15
71	A family with three germline mutations in <i>BRCA1</i> and <i>BRCA2</i> . <i>Clinical Genetics</i> , 1998, 54, 215-218.	2.0	13
72	Dietary intake of rosmarinic acid by <i>Apc^{Min}</i> mice, a model of colorectal carcinogenesis: levels of parent agent in the target tissue and effect on adenoma development. <i>Molecular Nutrition and Food Research</i> , 2012, 56, 775-783.	3.3	13

#	ARTICLE	IF	CITATIONS
73	Anthocyanins as tertiary chemopreventive agents in bladder cancer: anti-oxidant mechanisms and interaction with mitomycin C. <i>Mutagenesis</i> , 2014, 29, 227-235.	2.6	13
74	General practitioner attitudes towards prescribing aspirin to carriers of Lynch Syndrome: findings from a national survey. <i>Familial Cancer</i> , 2017, 16, 509-516.	1.9	13
75	Site-Specific Tamoxifen-DNA Adduct Formation: A Lack of Correlation with Mutational Ability in <i>Escherichia coli</i> . <i>Biochemistry</i> , 1999, 38, 10989-10996.	2.5	12
76	Short-term dosing of \pm -hydroxytamoxifen results in DNA damage but does not lead to liver tumours in female Wistar/Han rats. <i>Carcinogenesis</i> , 2001, 22, 553-557.	2.8	12
77	Consumption of silibinin, a flavonolignan from milk thistle, and mammary cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma (TAG) mouse. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 369-372.	2.3	11
78	Mutagenicity of tamoxifen DNA adducts in human endometrial cells and in silico prediction of p53 mutation hotspots. <i>Nucleic Acids Research</i> , 2008, 36, 5933-5945.	14.5	10
79	Effects of a Grapevine Shoot Extract Containing Resveratrol and Resveratrol Oligomers on Intestinal Adenoma Development in Mice: In Vitro and In Vivo Studies. <i>Molecular Nutrition and Food Research</i> , 2018, 62, 1700450.	3.3	10
80	New concepts and challenges in the clinical translation of cancer preventive therapies: the role of pharmacodynamic biomarkers. <i>Ecancermedicalscience</i> , 2015, 9, 601.	1.1	9
81	Inhibition of prostate cancer cell growth by 3,4,5-trimethoxyflavonol (TMFol). <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 179-185.	2.3	9
82	An HPLC-UV method for the simultaneous quantification of curcumin and its metabolites in plasma and lung tissue: Potential for preclinical applications. <i>Biomedical Chromatography</i> , 2018, 32, e4280.	1.7	9
83	Distribution and metabolism of [14 C]-resveratrol in human prostate tissue after oral administration of a dietary-achievable or pharmacological dose: what are the implications for anticancer activity?. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1115-1125.	4.7	8
84	APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo. <i>European Journal of Cancer</i> , 2009, 45, 2731-2735.	2.8	7
85	New Paradigms to Assess Consequences of Long-Term, Low-Dose Curcumin Exposure in Lung Cancer Cells. <i>Molecules</i> , 2020, 25, 366.	3.8	7
86	Characterization and Propagation of Tumor Initiating Cells Derived from Colorectal Liver Metastases: Trials, Tribulations and a Cautionary Note. <i>PLoS ONE</i> , 2015, 10, e0117776.	2.5	6
87	Synthesis of the flavonoid 3,4,5-trimethoxyflavonol and its determination in plasma and tissues of mice by HPLC with fluorescence detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 939-942.	2.3	5
88	Tissue distribution and metabolism of the putative cancer chemopreventive agent 3,4,5-trimethoxyflavonol (TMFol) in mice. <i>Biomedical Chromatography</i> , 2012, 26, 1559-1566.	1.7	5
89	Correspondence regarding M. Sharma et al., "Antioxidant inhibits tamoxifen-DNA adducts in endometrial explant culture". <i>Biochemical and Biophysical Research Communications</i> , 2003, 310, 1039.	2.1	4
90	Development of a novel site-specific mutagenesis assay using MALDI-ToF MS (SSMA-MS). <i>Nucleic Acids Research</i> , 2006, 34, e150-e150.	14.5	4

#	ARTICLE	IF	CITATIONS
91	Determination of 3â€™,4â€™,5â€™,7â€™pentamethoxyflavone in the plasma and intestinal mucosa of mice by HPLC with UV detection. Biomedical Chromatography, 2009, 23, 335-339.	1.7	3
92	Novel analogues of resveratrol: metabolism and inhibition of colon cancer cell proliferation. Tetrahedron, 2013, 69, 6203-6212.	1.9	3
93	Do Not Throw Out the Resveratrol With the Bath Water. JAMA Internal Medicine, 2015, 175, 140.	5.1	3
94	Abstract A104: 3â€™ TM , 4â€™ TM , 5â€™ TM -Trimethoxyflavonol (TMFol), a novel putative prostate cancer chemopreventive agent: In vitro and in vivo preclinical activity. , 2010, , .		3
95	Cancer chemoprevention. European Journal of Cancer Prevention, 2014, 23, 594-601.	1.3	2
96	Resveratrol for Cancer Prevention: Current Gaps and Opportunities. , 2020, , 19-47.		2
97	WITHDRAWALâ€”Administrative Duplicate Publication: The essential role of prevention in reducing the cancer burden in Europe: a commentary from Cancer Prevention Europe. Tumori, 2020, 106, NP2-NP4.	1.1	1
98	Response to comment on â€œCancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and miceâ€• Science Translational Medicine, 2016, 8, 350lr2.	12.4	0
99	Assessing barriers to a rational chemoprevention trial design in young patients with familial adenomatous polyposis. European Journal of Cancer Prevention, 2017, 26, 277-284.	1.3	0